P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension

Authors :: Petersen AnnKatrin
Usiskin Keith
Ghosh Subrata
Liu Wenzhong
Vermeire Severine
Hanauer Stephen
Feagan Brian
D'Haens Geert
Wolf Doug
Charles Lorna
Huang Vivian
Sandborn William
Source :: The American journal of gastroenterology. 115(Suppl 1)
Publication Year :: 2020

Subjects :: Moderate to severe
Ozanimod
medicine.medical_specialty
Hepatology
business.industry
Gastroenterology
MEDLINE
medicine.disease
Ulcerative colitis
chemistry.chemical_compound
chemistry
Internal medicine
Medicine
In patient
Long term safety
Open label
business

Tools